Business

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

PHILADELPHIA and VANCOUVER, British Columbia, March 05, 2026 (GLOBE NEWSWIRE) -- BriaCell Therap...

articleBriacell Therapeutics CorpMarch 5, 20264/company/briacell-therapeutics-corp/news/briacell-therapeutics-corp-announces-results-of-shareholder-meeting-47
BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

About this update from Briacell Therapeutics Corp

[{"type":"text","content":"BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting\nPHILADELPHIA and VANCOUVER, British Columbia, March 05, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce the results of its annual general and special meeting of shareholders of the Company (the “Shareholders”) for the year ended July 31, 2025 held on March 5, 2026 (the “Meeting”). A total of 48.31% of the Company’s issued and outstanding common shares (the “Common Shares”) were voted at the Meeting. At the Meeting, the Shareholders overwhelmingly voted in favour of all proposed resolutions, consisting of the re-appointment of MNP LLP as auditors of the Company for the ensuing year and authorizing the directors to fix their remuneration, and the election of each of Dr. William V. Williams, Mr. Jamieson Bondarenko, Dr. Jane A. Gross, Dr. Rebecca Taub, Mr. Vaughn C. Embro-Pantalony, and Mr. Martin E. Schmieg as directors of the Company. Detailed results of the votes in connection with the election of the directors are set out below: Director  % of Votes For  % of Votes WithheldDr. William V. Williams  97.38%  2.62%Mr. Jamieson Bondarenko  97.92%  2.08%Dr. Jane A. Gross  97.36%  2.64%Dr. Rebecca Taub  97.39%  2.61%Mr. Vaughn C. Embro-Pantalony  97.91%  2.09%Mr. Martin E. Schmieg  97.73%  2.27%        The formal report on voting results with respect to all matters voted upon during the Meeting will be filed on the Company’s SEDAR+ profile at www.sedarplus.ca. About BriaCell Therapeutics Corp. BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at https://briacell.com/. Safe Harbor This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Fo...

More updates from Briacell Therapeutics Corp